Ondine Biomedical - Grant of Options

Ondine Biomedical

26/02/2025 08:00

RNS Number : 4439Y

Ondine Biomedical Inc.

26 February 2025

 

26 February 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Grant of Options

Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces the grant of stock options to two key executives as part of the Company's ongoing commitment to attracting and retaining top-tier leadership.

On 25 February 2025, Ondine awarded a total of 9,315,286 options to subscribe for new common shares in the Company ("Options") to Dr. Nicolas Lobel, in recognition of his significant contributions to the development and advancement of Ondine's cutting-edge photodisinfection technology, and to Michael Behlke as part of his long-term compensation package. Details of the Options are as follows:

Director
Position
Options granted
Exercise price
Total options now held
Dr. Nicolas Loebel
President & Chief Technology Officer
6,000,000
11.25 pence
9,575,000
Michael Behlke
Chief Financial Officer & Chief Operating Officer (PDMR)
3,315,286
11.25 pence
3,315,286

The Options all have an exercise price of 11.25 pence, being the closing share price on 21 February 2025 (the "Approval Date"), the day on which the grant of Options was approved by the Board. The Options vest evenly over a period of 3 years from the Grant Date, with a third vesting on each of the three successive anniversaries of the Grant Date, and can be exercised for a period of eight years from the Grant Date.

Following the grant of Options, the Company has 22,420,286 options to subscribe for new common shares outstanding, which represents 5.07% of the Company's current issued share capital.

The FCA notifications in respect of the above Option grants, made in accordance with the requirements of the UK Market Abuse Regulations, are appended below.

Carolyn Cross, Ondine's Chief Executive Officer, commented:

"We are pleased to recognize the dedication and expertise of our leadership team. These option grants mark a key step in aligning leadership incentives with Ondine's long-term success.

"As we continue to expand our global footprint and advance our breakthrough infection prevention solutions, these options serve as a reflection of our commitment to driving shareholder value and attracting and retaining top talent."

The newly granted stock options will vest over 3 years, ensuring continued alignment with the Company's strategic objectives and long-term growth plans.

Enquiries, please contact:

Ondine Biomedical Inc.
www.ondinebio.com
Carolyn Cross, CEO
Via Vane Percy & Roberts
Strand Hanson Limited (Nominated & Financial Adviser)
James Harris, Richard Johnson
+44 (0)20 7409 3494
RBC Capital Markets (Broker)
Rupert Walford, Kathryn Deegan
+44 (0)20 7653 4000
Vane Percy & Roberts (Media Contact)
Simon Vane Percy, Amanda Bernard
+44 (0)77 1000 5910

 

 

 

About Ondine Biomedical Inc.

 

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies (also known as 'photodisinfection'). Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
1. Nicolas Lobel
2. Michael Behlke
2.
Reason for the Notification
a)
Position/status
1. President and CTO (PDMR)
2. CFO and COO (PDMR)
b)
Initial notification/Amendment
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Ondine Biomedical Inc.
b)
LEI
9845005B69E07CGF4A56
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the Financial instrument, type of instrument
Options to subscribe for Common Shares
Identification code
ISIN: CA68234M2058
b)
Nature of the transaction
Grant of options to subscribe for common shares of no par value
c)
Price(s) and volume(s)
PDMR
Price(s)
Volume(s)
Nicolas Lobel
Exercise price of 11.25 pence per share
6,000,000
Michael Behlke
Exercise price of 11.25 pence per share
3,315,286
d)
Aggregated information:
·Aggregated volume
·Price
N/A
e)
Date of the transaction
25 February 2025
f)
Place of the transaction
Outside a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHSELFAIEISELE